HomeAI · summaries
Storia in 7 fonti
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
washingtonexaminer.com
Treatment for millions at stake in 'skinny label' Supreme Court case
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.
- ·
medpagetoday.com
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
